Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP2202 in Relapsed/Refractory Multiple Myeloma
NCT07667868Phase 1Not yet recruiting
- Sponsor
- BrightPath Biotherapeutics Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Dec 2027
01
Overview
Phase 1, open-label, single-arm trial of BP2202 in multiple myeloma (MM), sponsored by BrightPath Biotherapeutics Co., Ltd. Primary endpoints: Incidence of dose-limiting toxicities at 6 weeks and Incidence of adverse events at 2 years. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
BP2202
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07667868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07667868.